RxDoctor Payments Data

Donald Stone, MD

Ophthalmology · Spokane Valley, WANPI 1790744860

Payments from drug & device makers

What this record shows

12 manufacturers reported payments, led by US Retina LLC at 48.0% of the total. 2025 is the largest year on record at $461, 2.8 times the $166 reported in 2019.

$1,388in general payments, 2019–2025

Across 30 payments — averaging $46.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • US Retina LLC$667
  • Biotissue Holdings Inc.$282
  • Dompe US, Inc.$211
  • AbbVie$48
  • Bausch & Lomb Americas Inc.$41
  • Lombart Brothers, Inc.$27
  • plus $112 from 6 others
$6,572in research payments, 2019–2025

Across 22 payments — averaging $298.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Glaukos Corporation$7K

What the payments were for

  • Food & beverage$72152%
  • Ownership interest$66748%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,388 in reported general payments places this provider in the 60th percentile of 428 ophthalmology providers in Washington.

See all ophthalmology providers in Washington

Medicare billing

Part B allowed, 2024
$333,642
Medicare patients
537
Services billed
2,034

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxervateCenegermin-Bkbj22$519,012
RestasisCyclosporine75$65,996
Restasis MultidoseCyclosporine50$37,271
XiidraLifitegrast47$32,877
Prednisolone Acetate389$14,217
Fluorometholone194$13,340
Cyclosporine29$10,392
Difluprednate70$7,024
ZirganGanciclovir11$5,974
Loteprednol Etabonate25$4,035
Famciclovir11$3,439
ValacyclovirValacyclovir Hcl83$2,813
Doxycycline Hyclate45$2,419
Tobramycin-DexamethasoneTobramycin/Dexamethasone39$1,921
Ketorolac Tromethamine83$1,900

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Dompe US, Inc.Oxervate$211$519,01222 claims
AbbVieRestasis, Restasis Multidose$48$103,267125 claims
Bausch & Lomb Americas Inc.Xiidra, Zirgan$41$38,85158 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$23$4,03525 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 428 ophthalmology providers in Washington.

Other ophthalmology in Spokane Valley

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →